专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017191323A1 PHARMACEUTICALLY ACTIVE PROTEIN CRYSTALS GROWN IN-SITU WITHIN A HYDROGEL 审中-公开
标题翻译：药物活性蛋白晶体在水凝胶内原位生长
公开(公告)号：WO2017191323A1
公开(公告)日：2017-11-09
申请号：PCT/EP2017/060842
申请日：2017-05-05
申请人： UNIVERSIDAD DE GRANADA , CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
发明人： ÁLVAREZ DE CIENFUEGOS RODRÍGUEZ, Luis , GAVIRA GALLARDO, José Antonio , DÍAZ MOCHÓN, Juan José , CONEJERO MURIEL, María Teresa , CONTRERAS MONTOYA, Rafael
IPC分类号： A61L27/52 , A61K38/28 , A61K38/52 , A61K47/18 , A61K47/42
CPC分类号： A61K38/28 , A61K38/52 , A61K47/183 , A61K47/42 , A61L27/52 , C12Y302/01017 , C12Y503/01005
摘要： The present invention providesa process to manufacture a composition comprising a hydrogel comprising pharmaceutically active protein crystals grown in-situwithin the hydrogel, wherein the pharmaceutically active protein crystals grown in-situhave an average size ofless than 20 microns, which comprises: a. Sequentially blending a pharmaceutically active protein solution in their appropriate buffer composition by using a value of supersaturation in the metastable zone width (MSZW) or nearby the supersolubility curve, with a precipitant solution, wherein acetone is absent, and a gelator solution, b. Inducing the nucleation by lowering the temperature, and c. Storing the resulting mixtureat a constant temperature, preferably at room temperatureat 1 atm.
摘要翻译：本发明提供了制备包含水凝胶的组合物的方法，所述水凝胶包含在水凝胶内原位生长的药学活性蛋白质晶体，其中原位生长的药学活性蛋白质晶体具有平均尺寸小于20微米，其中包括：a。通过使用沉淀剂溶液（其中不含丙酮）和胶凝剂溶液，使用亚稳区宽度（MSZW）或超溶解度曲线附近的过饱和值，将药学活性蛋白质溶液在其合适的缓冲剂组合物中连续混合，通过降低温度诱导成核，以及c。将得到的混合物储存在恒温下，优选室温下1个大气压下

2. 发明申请

WO2017100125A1 COMPOSITIONS AND METHODS FOR TREATING OR AMELIORATING NEUROINFLAMMATION, NEURODEGENERATION, NEUROPATHIC PAIN, AND MIGRAINE 审中-公开
标题翻译：用于治疗或改善神经性疼痛，神经退化，神经性疼痛和偏头痛的组合物和方法
公开(公告)号：WO2017100125A1
公开(公告)日：2017-06-15
申请号：PCT/US2016/064938
申请日：2016-12-05
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： MILLER, Yury , YAKSH, Tony L.
IPC分类号： A61K38/00 , A61K38/17 , A61P25/02 , C07K14/47 , C07K14/515 , C07K16/18
CPC分类号： C12Y501/99006 , A61K38/52 , A61K48/00 , A61P25/28 , A61P29/00 , C07K14/00 , C12N9/90
摘要： This invention generally relates to medicine, pain control and cell biology. In particular, provided are methods for increasing levels of and/or upregulating the expression of ApoA-1 Binding Protein (APOA1 BP, AIBP, or A1-BP) to treat, ameliorate, prevent, reverse, decrease the severity and/or duration of: a neuropathic pain, a CNS inflammation, an allodynia, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy (CIPN) a neurodcgeneration. In alternative embodiments, provided are methods comprising administering formulations and pharmaceutical compositions comprising an APOA1 BP polypeptide, a peptidomimetic or a synthetic APOA1 BP thereof, to treat, ameliorate prevent, reverse, decrease the severity of a neuropathic pain, an allodynia, a hyperalgesia, a neurodegenerative disease or condition such as Alzheimer's disease, and/or a primary headache such as a migraine. In alternative embodiments, provided are kits comprising a formulation or a pharmaceutical composition used in a method or use as provided herein.
摘要翻译：本发明一般涉及药物，疼痛控制和细胞生物学。具体而言，提供了用于增加和/或上调ApoA-1结合蛋白（APOA1BP，AIBP或A1-BP）表达水平和/或上调治疗，改善，预防，逆转，降低严重性和/或持续时间：神经性疼痛，CNS炎症，异常性疼痛，后神经损伤疼痛，术后疼痛，化疗诱导的周围神经病变（CIPN），神经再生。在替代实施方案中，提供了包括施用包含APOA1BP多肽，其拟肽或合成APOA1BP的制剂和药物组合物以治疗，改善预防，逆转，降低神经性疼痛的严重性，异常性疼痛，痛觉过敏，神经退行性疾病或病症如阿尔茨海默氏病，和/或原发性头痛如偏头痛。在替代实施方案中，提供了包含在本文提供的方法或用途中使用的制剂或药物组合物的试剂盒。

3. 发明申请

WO2015150771A1 CHIMERIC ANTIGEN RECEPTOR (CAR) SIGNALLING SYSTEM 审中-公开
标题翻译： CHIMERIC抗原受体（CAR）信号系统
公开(公告)号：WO2015150771A1
公开(公告)日：2015-10-08
申请号：PCT/GB2015/050974
申请日：2015-03-31
申请人： UCL BUSINESS PLC
发明人： PULÉ, Martin , CORDOBA, Shaun , KONG, Khai
IPC分类号： C07K14/705 , C07K16/28 , C12N5/0783 , A61K48/00
CPC分类号： A61K39/3955 , A61K31/166 , A61K31/436 , A61K31/4545 , A61K38/177 , A61K38/1774 , A61K38/45 , A61K38/52 , A61K2039/5156 , A61K2039/5158 , C07K14/4702 , C07K14/705 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N5/0636 , C12N5/0646 , C12N9/12 , C12N9/90 , C12Y207/11001 , C12Y502/01008
摘要： The present invention relates to a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an extracellular antigen-binding domain, a transmembrane domain and a intracellular first chemical inducer of dimerization binding domain 1 (CBD1 ); and (ii) an intracellular signalling component comprising a signalling domain and a second chemical inducer of dimerization binding domain 2 (CBD2); wherein CBD1 and CBD2 are capable of simultaneously binding to a chemical inducer of dimerization (CID); wherein, in the absence of the CID, binding of the antigen-binding component to antigen does not result in signalling through the signalling component; whilst, in the presence of the CID, the receptor component and the signalling component heterodimerize and binding of the antigen-binding domain to antigen results in signalling through the signalling domain.
摘要翻译：本发明涉及嵌合抗原受体（CAR）信号传导系统，其包含：（i）受体组分，其包含细胞外抗原结合结构域，跨膜结构域和二聚结合结构域1（CBD1）的细胞内第一化学诱导剂; 和（ii）包含信号结构域和二聚结合结构域2（CBD2）的第二化学诱导剂的细胞内信号传导成分; 其中CBD1和CBD2能够同时与二聚化学诱导剂（CID）结合; 其中，在没有CID的情况下，抗原结合组分与抗原的结合不会导致通过信号传导成分的信号传导; 而在CID存在下，受体组分和信号组分将抗原结合结构域与抗原异源二聚化和结合导致通过信号结构域的信号转导。

4. 发明申请

WO2014018663A1 EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS 审中-公开
标题翻译：从电解阿布肝类药物中分离的提取物及其在治疗疾病和病症中的应用
公开(公告)号：WO2014018663A1
公开(公告)日：2014-01-30
申请号：PCT/US2013/051871
申请日：2013-07-24
申请人： BIOQUARK, INC.
发明人： PAYLIAN, Sergei
IPC分类号： C12N13/00 , C12N5/00
CPC分类号： A61K35/65 , A61K31/7105 , A61K38/1703 , A61K38/45 , A61K38/46 , A61K38/52 , C12Y207/04006 , C12Y303/01001 , C12Y503/99002 , C12Y504/02002 , A61K2300/00
摘要： Methods for preparing a composition containing extracts of activated amphibian oocytes, the method where the composition is a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and a method for treating a disease, disorder, condition or injury characterized by a damaged or a cancerous differentiated cell including: (a) preparing the composition by the described method; (b) formulating a pharmaceutical composition comprising an equal volume of the extra-oocyte composition and the intra-oocyte composition, and optionally a carrier; and { c) administering a therapeutic amount of the pharmaceutical composition of (b) to a subject in need thereof, where the therapeutic amount as effective to reprogram the damaged or cancerous cells into iPSC-like cells capable of differentiating into cells capable of repairing the damaged or cancerous cells, thereby treating the disease, disorder, injury or condition.
摘要翻译：用于制备含有活化的两栖动物卵母细胞提取物的组合物的方法，所述组合物是包含等体积卵母细胞组合物和卵母细胞组合物的药物组合物的方法，以及治疗疾病，病症，病况或特征在于损伤或癌分化细胞的损伤，包括：（a）通过所述方法制备组合物; （b）配制包含等体积卵母细胞组合物和卵母细胞组合物以及任选的载体的药物组合物; （c）向有需要的受试者施用治疗量的（b）的药物组合物，其中有效地将损伤或癌细胞重新编程成能够分化成能够修复细胞的细胞的iPSC样细胞的治疗量损伤或癌细胞，从而治疗疾病，障碍，损伤或病症。

5. 发明申请

WO2012071525A3 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH D-DT 审中-公开
标题翻译：诊断和治疗与D-DT有关的疾病和病症的组合物和方法
公开(公告)号：WO2012071525A3
公开(公告)日：2012-08-16
申请号：PCT/US2011062062
申请日：2011-11-23
申请人： UNIV YALE , BUCALA RICHARD J , YOUNG LAWRENCE H
发明人： BUCALA RICHARD J , YOUNG LAWRENCE H
IPC分类号： C12Q1/00 , C12Q1/68 , G01N33/53
CPC分类号： G01N33/6893 , A61K31/713 , A61K38/02 , A61K38/52 , A61K39/3955 , A61K2039/505 , C07K16/24 , C07K16/40 , C07K2317/24 , C07K2317/622 , C07K2317/76 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/141 , C12Q1/6883 , C12Q2600/158 , C12Y503/03012 , G01N2333/99
摘要： The present invention relates to the discovery that altered levels of D- DT (also known as MIF-2) are associated with disorders and diseases. Thus, the present invention relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with an elevated level of D-DT, The present invention also relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with a reduced level of D-DT.
摘要翻译：本发明涉及改变水平的D-DT（也称为MIF-2）与病症和疾病相关的发现。因此，本发明涉及可用于评估，诊断，表征，预防和治疗与升高水平的D-DT相关的病症和疾病的组合物和方法。本发明还涉及用于评估，诊断，表征，预防和治疗与D-DT水平降低有关的疾病和疾病。

6. 发明申请

WO2012019154A2 METHODS AND COMPOSITIONS FOR MALIC ENZYME 2 (ME2) AS A TARGET FOR CANCER THERAPY 审中-公开
标题翻译：作为癌症治疗目标的MALIC ENZYME 2（ME2）的方法和组合
公开(公告)号：WO2012019154A2
公开(公告)日：2012-02-09
申请号：PCT/US2011046841
申请日：2011-08-05
申请人： BETH ISRAEL HOSPITAL , SUKHATME VIKAS P , REN JIAN-GUO
发明人： SUKHATME VIKAS P , REN JIAN-GUO
IPC分类号： A61K48/00
CPC分类号： A61K39/3955 , A61K31/196 , A61K31/198 , A61K31/282 , A61K31/335 , A61K31/336 , A61K31/337 , A61K31/506 , A61K31/555 , A61K31/56 , A61K31/7052 , A61K31/7105 , A61K31/713 , A61K33/00 , A61K33/24 , A61K38/52 , A61K45/06 , C12N15/1137 , C12N2330/51 , C12Y101/01037 , G01N33/57484 , G01N2333/904 , G01N2500/10 , C12N2310/14 , C12N2310/531
摘要： The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.
摘要翻译：本发明涉及用于治疗和诊断导致苹果酶2失调的癌症和其它相关疾病的方法，组合物和诊断测试。特别地，所述方法和组合物包括组合疗法，例如两种或多种 ME2抑制剂或ME2抑制剂与抗癌剂的组合。

7. 发明申请

WO2010025483A8 TREATMENT OF FRUCTOSE MALABSORPTION 审中-公开
标题翻译：治疗果糖吸收障碍
公开(公告)号：WO2010025483A8
公开(公告)日：2010-05-14
申请号：PCT/AT2009000314
申请日：2009-08-19
申请人： SCIOTEC DIAGNOSTIC TECHNOLOGIE , MISSBICHLER ALBERT
发明人： MISSBICHLER ALBERT
IPC分类号： A61K38/52 , A61K33/32 , A61P1/14
CPC分类号： A61K38/52 , A61K33/32 , C12Y503/01005 , A61K2300/00
摘要： The present invention relates to a composition comprising crystalline xylose isomerase (EC 5.3.1.5) and at least one salt of a metal and/or alkaline earth metal.
摘要翻译：本发明涉及包含结晶木糖异构酶（EC 5.3.1.5）和至少一种金属和/或碱土金属盐的组合物。

8. 发明申请

WO2007093807A2 APOPTOSIS METHODS, GENES AND PROTEINS 审中-公开
标题翻译：病毒学方法，基因和蛋白质
公开(公告)号：WO2007093807A2
公开(公告)日：2007-08-23
申请号：PCT/GB2007/000540
申请日：2007-02-15
申请人： MORVUS TECHNOLOGY LIMITED , CHAUDHURI, Bhabatosh
发明人： CHAUDHURI, Bhabatosh
IPC分类号： C07K14/47 , C12N15/81
CPC分类号： C07K14/4747 , A61K38/00 , A61K38/1709 , A61K38/1716 , A61K38/177 , A61K38/52 , C12Y502/01008 , G01N2510/00
摘要： A W303a Saccharomyces cerevisiae yeast cell which contains a polynucleotide that encodes a functional Bax polypeptide under the control of a galactose- inducible promoter that is integrated at the LEU2 chromosomal locus. A kit of parts comprising the yeast cells and a yeast plasmid vector suitable for transforming a cDNA library into the yeast cells. Use of the yeast cell for screening a cDNA library for a polynucleotide that is or encodes an inhibitor of B ax-mediated apoptosis. Genes and polypeptides that inhibit Bax-mediated apoptosis and which were identified from a human hippocampus cDNA library screened in the yeast cells. A method of combating Bax-mediated apoptosis in a cell using an inhibitor of Bax-mediated apoptosis which was identified from a human hippocampus cDNA library screened in the yeast cells. A method of promoting Bax-mediated apoptosis in a cell using an inhibitor or antagonist of the anti-apoptotic polypeptides identified from a human hippocampus cDNA library screened in the yeast cells.
摘要翻译：一种W303a酿酒酵母酵母细胞，其含有编码在整合在LEU2染色体基因座的半乳糖诱导型启动子控制下的功能性Bax多肽的多核苷酸。包含酵母细胞的一组试剂盒和适用于将cDNA文库转化到酵母细胞中的酵母质粒载体。使用酵母细胞筛选用于编码B ax介导的凋亡抑制剂的多核苷酸的cDNA文库。抑制Bax介导的凋亡的基因和多肽，并且从在酵母细胞中筛选的人海马cDNA文库中鉴定。使用Bax介导的凋亡抑制剂在细胞中抗Bax介导的细胞凋亡的方法，其由在酵母细胞中筛选的人海马cDNA文库鉴定。使用从酵母细胞中筛选的人海马cDNA文库鉴定的抗凋亡多肽的抑制剂或拮抗剂促进细胞中Bax介导的细胞凋亡的方法。

9. 发明申请

WO2006124699A2 BLOCKADE OF PIN1 PREVENTS CYTOKINE PRODUCTION BY ACTIVATED IMMUNE CELLS 审中-公开
标题翻译： PIN1的阻断剂通过激活的免疫细胞预防细胞因子生成
公开(公告)号：WO2006124699A2
公开(公告)日：2006-11-23
申请号：PCT/US2006018591
申请日：2006-05-12
申请人： WISCONSIN ALUMNI RES FOUND , MALTER JAMES S , ESNAULT STEPHANE , SHEN ZHONG-JIAN
发明人： MALTER JAMES S , ESNAULT STEPHANE , SHEN ZHONG-JIAN
CPC分类号： A61K38/52 , A61K31/12 , A61K38/13
摘要： The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil apoptosis, and methods for treating eosinophil-associated disorders comprising inducing eosinophil apoptosis in an individual in need thereof.
摘要翻译：本发明提供药物组合物和治疗免疫疾病的方法。本发明还提供了诱导嗜酸性粒细胞凋亡的药物组合物和方法，以及用于治疗嗜酸性粒细胞相关病症的方法，包括在有需要的个体中诱导嗜酸性粒细胞凋亡。

10. 发明申请

WO2006094344A1 METHODS AND AGENTS FOR REGULATING CELLULAR INTERACTIONS AND DEVELOPMENT 审中-公开
标题翻译：调节细胞相互作用和发展的方法和代理
公开(公告)号：WO2006094344A1
公开(公告)日：2006-09-14
申请号：PCT/AU2006/000298
申请日：2006-03-07
申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , HILTON, Douglas, J. , ALEXANDER, Warren, S. , KILE, Benjamin, T. , GREIG, Kylie, T. , ANTONCHUK, Jennifer, L. R. , METCALF, Donald , ZHANG, Jian-Guo , KREBS, Danielle, L. , MORGAN, Phillip, O.
发明人： HILTON, Douglas, J. , ALEXANDER, Warren, S. , KILE, Benjamin, T. , GREIG, Kylie, T. , ANTONCHUK, Jennifer, L. R. , METCALF, Donald , ZHANG, Jian-Guo , KREBS, Danielle, L. , MORGAN, Phillip, O.
IPC分类号： A61K38/52 , A61P7/00 , A61K48/00 , A61P15/08
CPC分类号： A61K38/52 , A61K38/02 , A61K48/00 , C12Q1/25 , G01N2500/04 , G01N2800/22 , G01N2800/367
摘要： The present invention discloses the use of agents that modulate the level or distribution of UDP-GlcNAc, or its transporter, in a cell to regulate cellular development and particularly, their use in the treatment or prophylaxis of defects or conditions in mammalian subjects.
摘要翻译：本发明公开了调节UDP-GlcNAc或其转运蛋白在细胞中调节细胞发育的水平或分布的试剂的用途，特别是其用于治疗或预防哺乳动物受试者中缺陷或病症的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式